Financials in USD. Standardized financial statements.
A compact view of how SymBio Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.37B | $2.45B | $5.59B | $10.01B | $8.25B | $2.99B | $2.84B | $3.84B | $3.44B | $2.37B |
| Revenue Growth? | -44.1% | -56.1% | -44.1% | +21.3% | +176.3% | +5.3% | -26.0% | +11.4% | +45.4% | 0.0% |
| Cost of Revenue? | $377.78M | $579.72M | $1.18B | $2.41B | $2.45B | $2.12B | $1.97B | $2.66B | $2.41B | $1.46B |
| Gross Profit? | $993.27M | $1.87B | $4.41B | $7.60B | $5.80B | $866.85M | $864.75M | $1.17B | $1.03B | $904.19M |
| Gross Margin? | +72.4% | +76.4% | +78.9% | +75.9% | +70.3% | +29.0% | +30.5% | +30.6% | +29.9% | +38.2% |
| Operating Expenses? | $5.65B | $5.75B | $5.22B | $5.64B | $4.78B | $5.37B | $5.17B | $3.83B | $4.98B | $3.03B |
| Operating Income? | -$4.66B | -$3.88B | -$811.67M | $1.96B | $1.02B | -$4.51B | -$4.30B | -$2.66B | -$3.95B | -$2.13B |
| EBITDA? | -$4.82B | -$3.78B | -$715.66M | $2.06B | $1.11B | -$4.44B | -$4.26B | -$2.62B | -$3.92B | -$2.10B |
| Income Before Tax | -$4.98B | -$3.81B | -$1.20B | $2.11B | $1.00B | -$4.09B | -$4.37B | -$2.75B | -$3.97B | -$2.31B |
| Income Tax Expense | $28.91M | $26.52M | $767.43M | $927.04M | -$1.03B | $3.80M | $3.80M | $3.80M | $3.80M | $3.80M |
| Net Income? | -$5.01B | -$3.83B | -$1.96B | $1.18B | $2.03B | -$4.09B | -$4.38B | -$2.75B | -$3.98B | -$2.31B |
| EPS? | $-99.73 | $-84.06 | $-49.19 | $30.20 | $53.04 | $-124.13 | $-189.03 | $-165.54 | $-319.14 | $-235.27 |
| Diluted EPS? | $-99.73 | $-84.06 | $-49.19 | $29.77 | $52.32 | $-124.13 | $-189.03 | $-165.54 | $-319.14 | $-235.27 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality